B48.3 Geotrichosis

Name of the Condition

• Geotrichosis

Summary

Geotrichosis is a fungal infection caused by Geotrichum species, typically affecting the respiratory tract, skin, or mucous membranes. The condition may present with localized or systemic manifestations, depending on the site of infection and host immune status. Geotrichum is an environmental fungus found in soil, water, and decaying organic matter, and infections often occur in immunocompromised individuals or those with underlying lung disease.

Causes

The infection is caused by Geotrichum species, which are saprophytic fungi ubiquitous in the environment. Transmission occurs through inhalation of fungal spores or direct contact with contaminated surfaces. The organism can colonize the respiratory tract or invade tissues in susceptible hosts, leading to infection.

Risk Factors

• Immunocompromised states (e.g., HIV/AIDS, chemotherapy, organ transplantation).
• Chronic lung diseases (e.g., COPD, bronchiectasis).
• Prolonged use of broad-spectrum antibiotics or corticosteroids.
• Hospitalization or exposure to healthcare settings with environmental contamination.
• Underlying malignancies or malnutrition.

Symptoms

• Respiratory symptoms: cough, dyspnea, fever, or chest pain (if pulmonary involvement).
• Mucocutaneous lesions: white, cheesy plaques on oral or vaginal mucosa; erythematous, scaling skin lesions.
• Systemic infection: rare but may cause sepsis in severely immunocompromised patients.
• Asymptomatic colonization is common in at-risk populations.

Diagnosis

Diagnosis is confirmed by identifying Geotrichum in clinical specimens (e.g., sputum, tissue biopsy, or cultures). Microscopic examination may show characteristic septate hyphae or arthroconidia. Culture on Sabouraud dextrose agar helps isolate the organism, and molecular testing (e.g., PCR) can aid in species identification. Histopathology may reveal fungal elements in tissue samples.

Treatment Options

• Antifungal therapy: Itraconazole, voriconazole, or amphotericin B (for severe cases).
• Supportive care: Oxygen therapy, bronchodilators, or wound care for localized infections.
• Addressing underlying risk factors (e.g., reducing immunosuppression) is critical.
• Surgical debridement may be necessary for invasive or refractory infections.

Prognosis and Follow-Up

Prognosis depends on the host’s immune status and extent of infection. Immunocompetent patients with localized disease typically respond well to treatment. Immunocompromised individuals may experience prolonged or recurrent infections, requiring ongoing monitoring. Follow-up cultures and clinical assessments ensure treatment efficacy and detect relapse.

Complications

• Chronic pulmonary infection or bronchiectasis.
• Disseminated disease in severely immunocompromised patients.
• Secondary bacterial infections of skin or mucosal lesions.
• Respiratory failure in advanced pulmonary cases.

Lifestyle & Prevention

• Avoid exposure to moldy environments (e.g., damp buildings, decaying organic matter).
• Use protective equipment (e.g., masks) in high-risk settings (e.g., construction, agriculture).
• Maintain good hygiene and wound care to prevent skin inoculation.
• For immunocompromised patients, minimize exposure to potential fungal reservoirs.

When to Seek Professional Help

Seek medical attention if respiratory symptoms (e.g., persistent cough, fever) or mucocutaneous lesions develop, especially in immunocompromised individuals. Prompt evaluation is necessary for suspected invasive infection to initiate timely treatment.

Tips for Medical Coders

Code B48.3 is specific to geotrichosis. Documentation should specify the site of infection (e.g., pulmonary, cutaneous) and any associated risk factors (e.g., immunocompromised state) to support accurate coding. Ensure the diagnosis is confirmed by laboratory testing (e.g., culture, histopathology) and that the code aligns with the clinical presentation.